The reports on relationship of obesity and biochemical or clinical recurrence of prostate cancer are controversial. Several reports have shown that obesity is associated with increased risk of biochemical or clinical failure after radical prostatectomy. Other prospective studies have shown no adverse effect of obesity on long-term outcomes after prostatectomy. Limited reports are available on the impact of obesity on prostate cancer progression after radiotherapy. Primary: to assess percentage recurrence rate among normal weight and overweight or obese prostate cancer patients treated by adjuvant Zoladex therapy. Secondary: to determine the Quality of Life differences among normal and overweight or obese prostate cancer patients by a Quality of Life questionnaire
Study Type
OBSERVATIONAL
Enrollment
1,376
Research Site
Baja, Hungary
Research Site
Barcs, Hungary
Research Site
Békés, Hungary
Research Site
Békéscsaba, Hungary
Research Site
Budapest, Hungary
Research Site
Csongrád, Hungary
Research Site
Debrecen, Hungary
Research Site
Dunaharaszti, Hungary
Research Site
Dunaújváros, Hungary
Research Site
Győr, Hungary
...and 24 more locations
Percentage recurrence rate among normal weight and overweight or obese prostate cancer patients treated by adjuvant Zoladex therapy.
Time frame: Every 3 months
Quality of Life differences among normal and overweight or obese prostate cancer patients by a Quality of Life questionnaire
Time frame: Every 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.